Olmesartan 144689-63-4
Olmesartan (trade names Benicar, Olmetec) is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug olmesartan medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and in India by Zydus Cadila under the trade name Olmy and by Ranbaxy Laboratories Ltd. under the trade name Olvance.
Adverse effects
Adverse effects include headache, dizziness, diarrhea, hyperglycemia, flu-like symptoms, tachycardia, and upper respiratory tract infection. Olmesartan does not cause cough more frequently than placebo does.
Mechanism of action
Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.
| Systematic (IUPAC) name: | (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate |
|---|---|
| Olmesartan CAS number: | 144689-63-4 |
| ATC code: | C09CA08 C09DA08(with[[diuretics]])C09DB02(with[[amlodipine]]) |
| PubChem: | 130881 |
| DrugBank: | APRD00223 |
| Formula: | C29H30N6O6 |
| Molecular mass: | 558.585 g/mol |
| Olmesartan Assay/Purity: | Typically NLT 98% |
